Jasper Therapeutics (JSPR) Income from Continuing Operations (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Income from Continuing Operations of 15997000.0 for Q4 2025, up 35.08% year-over-year from 11842634.13 in Q4 2024, and up 15.27% quarter-over-quarter from 18879000.0 in Q3 2025.
Jasper Therapeutics (JSPR) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 15997000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 35.08% year-over-year to 15997000.0; the TTM figure through Dec 2025 stood at 85077000.0 (down 11.17% YoY), while the FY2025 annual figure was 83965000.0, down 7.94% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 15997000.0, up from 18879000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 5498071.0 in Q1 2021, with the low at 28886000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 15509000.0 (2024), against an average of 15380423.15.
- Peak annual rise in Income from Continuing Operations reached 284.79% in 2021, while the deepest fall reached 4536.03% in 2021.
- Jasper Therapeutics' Income from Continuing Operations stood at 11929000.0 in 2021, then decreased by 19.41% to 14245000.0 in 2022, then slipped by 17.77% to 16776000.0 in 2023, then slumped by 46.88% to 24641000.0 in 2024, then surged by 35.08% to 15997000.0 in 2025.
- Business Quant data shows JSPR's Income from Continuing Operations at 15997000.0 in Q4 2025, 18879000.0 in Q3 2025, and 28886000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Jasper Therapeutics | 20.06 Mn | 20.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16.00 Mn |
| Sep 30, 2025 | -18.88 Mn |
| Jun 30, 2025 | -28.89 Mn |
| Mar 31, 2025 | -21.32 Mn |
| Dec 31, 2024 | -24.64 Mn |
| Sep 30, 2024 | -22.47 Mn |
| Jun 30, 2024 | -15.02 Mn |
| Mar 31, 2024 | -14.40 Mn |
| Dec 31, 2023 | -16.78 Mn |
| Sep 30, 2023 | -21.29 Mn |
| Jun 30, 2023 | -17.58 Mn |
| Mar 31, 2023 | -13.13 Mn |
| Dec 31, 2022 | -14.25 Mn |
| Sep 30, 2022 | -13.19 Mn |
| Jun 30, 2022 | -11.97 Mn |
| Mar 31, 2022 | -17.74 Mn |
| Dec 31, 2021 | -11.93 Mn |
| Sep 30, 2021 | -10.08 Mn |
| Jun 30, 2021 | -3.57 Mn |
| Mar 31, 2021 | 5.50 Mn |